We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
GKOS sees iDose re-administration creating a recurring treatment opportunity as patients remain on therapy.
Epioxa generated $11 million in Q2, with broad payer access and treatment-center infrastructure in place.
High gross margins and a broad pipeline spanning five platforms support Glaukos' growth prospects.
Glaukos Corporation’s (GKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.
Shares of this Zacks Rank #3 (Hold) company have gained 35.9% so far this year against the industry’s 5.5% decline. The S&P 500 Index has increased 13% in the same time frame.
Glaukos, with a market capitalization of $9.43 billion, is a leading ophthalmic medical technology and pharmaceutical company. It has a trailing four-quarter average earnings surprise of 25.87%.
Image Source: Zacks Investment Research
Positive Factors Driving Prospects
iDose re-administration Could Create a Recurring Treatment Opportunity: An important upside for iDose is that re-administration appears to be additive rather than cannibalistic to the initial implant opportunity. Management reported that eligible early commercial patients are successfully undergoing re-administration as their initial iDose therapy wears off, with physicians and patients choosing to remain on the treatment. This creates the potential for a recurring treatment cycle rather than a one-time procedure opportunity.
Future products such as iDose TREX could further strengthen this treatment algorithm. As the installed base of iDose patients expands, successful re-administration could increase lifetime revenue per treated patient while reinforcing physician familiarity with Glaukos’ interventional glaucoma platform.
Epioxa Has the Potential for a Scalable Commercial Infrastructure: Epioxa generated sales worth approximately $11 million in the second quarter, its first full quarter of commercial availability. Glaukos has already established access pathways covering more than 125 million U.S. commercial lives, including the five largest payers. Its O2N treatment-center network reaches locations serving roughly 85% of the U.S. population, with expectations to reach approximately 95% in the pipeline. The permanent J-code became effective on July 1, potentially simplifying reimbursement and claims processing. These infrastructure milestones are important because Epioxa's opportunity depends not only on physician adoption but also on diagnosis, referral, reimbursement and treatment-site availability.
High Gross Margins Provide Significant Operating-Leverage Potential: Glaukos’ business model is showing strong gross-margin leverage as higher-value products become a larger portion of revenues. Gross margin reached approximately 85% in the second quarter, up about 90 basis points sequentially.
Management attributed the improvement primarily to increasing contributions from iDose and Epioxa. The company expects further modest gross-margin accretion, particularly in the fourth quarter, as these products represent a larger share of the revenue mix.
Maintaining an 84-86% full-year gross-margin target while rapidly expanding revenues creates substantial potential for operating leverage, provided commercial and R&D investment grows more slowly than revenues.
Glaukos Is Building Several Growth Platforms Beyond iDose and Epioxa: The company’s longer-term opportunity is supported by a broad pipeline spanning five novel therapeutic platforms and 13 publicly disclosed programs. Within the iDose family, TREX is advancing through Phase IIb/III while TRIO is targeted for FDA approval by the end of 2027. The iLink platform is preparing for a KC screening-device launch later this year and a Phase III program in 2027.
PRESERFLO, Demodex blepharitis and GLK-401 expand the potential into additional glaucoma, ocular-surface and retinal indications. This diversification could reduce dependence on any single product while creating multiple potential catalysts over the next several years.
Key Challenges
iDose Growth Could Moderate After an Exceptionally Strong Q2: Although iDose delivered exceptional second-quarter momentum, management remains cautious about extrapolating the quarter because it represents an early stage of the commercial launch. The company specifically noted that the third quarter is seasonally weaker for ophthalmology procedures and wants to see another one or two quarters before determining whether second-quarter growth represents a sustainable trend.
Consequently, the 2026 iDose outlook of approximately $275-$280 million implies relatively limited sequential growth in the second half. A normalization in procedure volumes, slower account utilization or a more gradual reimbursement ramp up could therefore create quarterly volatility, particularly against the exceptionally strong second-quarter comparison.
Epioxa’s Reimbursement Model Could Pressure Realized Pricing: While Epioxa’s market-access progress is encouraging, its realized economics remain subject to payer mix and mandatory discounts. Management currently views approximately $60,000 as a reasonable starting point for net realized revenue per treatment, incorporating Medicaid pricing, 340B-related volume and other required discounts.
The company is still developing its mix between specialty-pharmacy and buy-and-bill channels. Community practices initially appear more dependent on specialty pharmacy, while larger institutions with reimbursement experience are more comfortable with buy-and-bill. As the commercial model matures, changes in payer mix, contracting and channel utilization could influence Epioxa’s realized revenue per procedure.
International Glaucoma Growth Faces Headwinds: Glaukos' international glaucoma franchise remains healthy, but its growth outlook incorporates several emerging challenges. International glaucoma revenues increased 17% reportedly and 16% on a constant-currency basis in the second quarter. However, management expects new competitive product trialing to create headwinds across certain major markets.
Reimbursement pressure has emerged in Germany and Switzerland, while foreign-exchange tailwinds are expected to disappear over the second half. Although PreserFlo, iStent infinite and broader MIGS adoption should offset some pressure, the combination of competition, reimbursement changes and less favorable currency translation could moderate international growth. Management expects low-to-mid-teens growth for the full year, implying a stronger second-half execution requirement.
Heavy Investment Could Delay Full Profitability Despite Revenue Growth: Glaukos is generating substantial revenue growth, but management continues to prioritize investment in commercial infrastructure and its clinical pipeline. R&D spending increased sequentially as the company expanded its clinical programs, while management reiterated that commercial investments supporting iDose and Epioxa remain a priority.
The company has a clear path toward profitability (given its high gross-margin profile), but the timing depends partly on how aggressively it reinvests incremental revenues into launches and clinical development. With operating expenses now expected to reach approximately $600 million in 2026, stronger-than-expected revenues may not translate proportionately into earnings if management continues to accelerate investments in its growth platforms.
The Zacks Consensus Estimate for 2026 revenues is pegged at $689.7 million, indicating a 36% improvement from the previous year’s level.
The consensus mark for loss per share is pinned at 32 cents, indicating a 64.4% improvement from the year-ago reported number. The consensus estimate for loss per share has narrowed 43.9% in the past 60 days.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain Glaukos Stock in Your Portfolio for Now
Key Takeaways
Glaukos Corporation’s (GKOS - Free Report) growth prospects are supported by the continued expansion of interventional glaucoma, growing clinical and commercial synergies between iDose TR and iStent infinite, and the potential for long-term operating leverage. However, physician workflow challenges, infrastructure constraints and margin pressure remain key risks.
Shares of this Zacks Rank #3 (Hold) company have gained 35.9% so far this year against the industry’s 5.5% decline. The S&P 500 Index has increased 13% in the same time frame.
Glaukos, with a market capitalization of $9.43 billion, is a leading ophthalmic medical technology and pharmaceutical company. It has a trailing four-quarter average earnings surprise of 25.87%.
Image Source: Zacks Investment Research
Positive Factors Driving Prospects
iDose re-administration Could Create a Recurring Treatment Opportunity: An important upside for iDose is that re-administration appears to be additive rather than cannibalistic to the initial implant opportunity. Management reported that eligible early commercial patients are successfully undergoing re-administration as their initial iDose therapy wears off, with physicians and patients choosing to remain on the treatment. This creates the potential for a recurring treatment cycle rather than a one-time procedure opportunity.
Future products such as iDose TREX could further strengthen this treatment algorithm. As the installed base of iDose patients expands, successful re-administration could increase lifetime revenue per treated patient while reinforcing physician familiarity with Glaukos’ interventional glaucoma platform.
Epioxa Has the Potential for a Scalable Commercial Infrastructure: Epioxa generated sales worth approximately $11 million in the second quarter, its first full quarter of commercial availability. Glaukos has already established access pathways covering more than 125 million U.S. commercial lives, including the five largest payers. Its O2N treatment-center network reaches locations serving roughly 85% of the U.S. population, with expectations to reach approximately 95% in the pipeline. The permanent J-code became effective on July 1, potentially simplifying reimbursement and claims processing. These infrastructure milestones are important because Epioxa's opportunity depends not only on physician adoption but also on diagnosis, referral, reimbursement and treatment-site availability.
High Gross Margins Provide Significant Operating-Leverage Potential: Glaukos’ business model is showing strong gross-margin leverage as higher-value products become a larger portion of revenues. Gross margin reached approximately 85% in the second quarter, up about 90 basis points sequentially.
Management attributed the improvement primarily to increasing contributions from iDose and Epioxa. The company expects further modest gross-margin accretion, particularly in the fourth quarter, as these products represent a larger share of the revenue mix.
Maintaining an 84-86% full-year gross-margin target while rapidly expanding revenues creates substantial potential for operating leverage, provided commercial and R&D investment grows more slowly than revenues.
Glaukos Is Building Several Growth Platforms Beyond iDose and Epioxa: The company’s longer-term opportunity is supported by a broad pipeline spanning five novel therapeutic platforms and 13 publicly disclosed programs. Within the iDose family, TREX is advancing through Phase IIb/III while TRIO is targeted for FDA approval by the end of 2027. The iLink platform is preparing for a KC screening-device launch later this year and a Phase III program in 2027.
PRESERFLO, Demodex blepharitis and GLK-401 expand the potential into additional glaucoma, ocular-surface and retinal indications. This diversification could reduce dependence on any single product while creating multiple potential catalysts over the next several years.
Key Challenges
iDose Growth Could Moderate After an Exceptionally Strong Q2: Although iDose delivered exceptional second-quarter momentum, management remains cautious about extrapolating the quarter because it represents an early stage of the commercial launch. The company specifically noted that the third quarter is seasonally weaker for ophthalmology procedures and wants to see another one or two quarters before determining whether second-quarter growth represents a sustainable trend.
Consequently, the 2026 iDose outlook of approximately $275-$280 million implies relatively limited sequential growth in the second half. A normalization in procedure volumes, slower account utilization or a more gradual reimbursement ramp up could therefore create quarterly volatility, particularly against the exceptionally strong second-quarter comparison.
Epioxa’s Reimbursement Model Could Pressure Realized Pricing: While Epioxa’s market-access progress is encouraging, its realized economics remain subject to payer mix and mandatory discounts. Management currently views approximately $60,000 as a reasonable starting point for net realized revenue per treatment, incorporating Medicaid pricing, 340B-related volume and other required discounts.
The company is still developing its mix between specialty-pharmacy and buy-and-bill channels. Community practices initially appear more dependent on specialty pharmacy, while larger institutions with reimbursement experience are more comfortable with buy-and-bill. As the commercial model matures, changes in payer mix, contracting and channel utilization could influence Epioxa’s realized revenue per procedure.
International Glaucoma Growth Faces Headwinds: Glaukos' international glaucoma franchise remains healthy, but its growth outlook incorporates several emerging challenges. International glaucoma revenues increased 17% reportedly and 16% on a constant-currency basis in the second quarter. However, management expects new competitive product trialing to create headwinds across certain major markets.
Reimbursement pressure has emerged in Germany and Switzerland, while foreign-exchange tailwinds are expected to disappear over the second half. Although PreserFlo, iStent infinite and broader MIGS adoption should offset some pressure, the combination of competition, reimbursement changes and less favorable currency translation could moderate international growth. Management expects low-to-mid-teens growth for the full year, implying a stronger second-half execution requirement.
Heavy Investment Could Delay Full Profitability Despite Revenue Growth: Glaukos is generating substantial revenue growth, but management continues to prioritize investment in commercial infrastructure and its clinical pipeline. R&D spending increased sequentially as the company expanded its clinical programs, while management reiterated that commercial investments supporting iDose and Epioxa remain a priority.
The company has a clear path toward profitability (given its high gross-margin profile), but the timing depends partly on how aggressively it reinvests incremental revenues into launches and clinical development. With operating expenses now expected to reach approximately $600 million in 2026, stronger-than-expected revenues may not translate proportionately into earnings if management continues to accelerate investments in its growth platforms.
Glaukos Corporation Price
Glaukos Corporation price | Glaukos Corporation Quote
Estimate Trend
The Zacks Consensus Estimate for 2026 revenues is pegged at $689.7 million, indicating a 36% improvement from the previous year’s level.
The consensus mark for loss per share is pinned at 32 cents, indicating a 64.4% improvement from the year-ago reported number. The consensus estimate for loss per share has narrowed 43.9% in the past 60 days.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Veracyte (VCYT - Free Report) and West Pharmaceutical (WST - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Veracyte, currently flaunting a Zacks Rank #1, reported a second-quarter 2026 adjusted EPS of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%.
VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.
West Pharmaceutical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 17.4%.